NGM · Medical - Devices
TLSI (TLSI) Stock
$4.35
+0.69%
NGM: TLSI
Healthcare
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
TriSalus Life Sciences to Host Second Quarter 2026 Financial Results Conference Call
Business Wire · Jul 16, 2026
QuidelOrtho (QDEL) Moves 32.2% Higher: Will This Strength Last?
Zacks · Jun 30, 2026
TriSalus Life Sciences to Host Virtual KOL Event on June 24 Featuring New Real-World Evidence for Pressure-Enabled Drug Delivery™ in Liver Cancer
Business Wire · Jun 10, 2026
Top Midday Decliners
MT Newswires · May 13, 2026
TriSalus Life Sciences Inc (TLSI) Q1 2026 Earnings Call Highlights: Strategic Expansion and ...
GuruFocus.com · May 13, 2026
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Insiders Held34.05%
Institutions Held34.59%
Institutions Float Held52.44%
Peer Comparison
About TLSI
TLSI is led by CEO Mary T. Szela, employs 110 people, headquartered in US, publicly traded since 2021.
TLSI stock trades at $4.35 with a market capitalization of $164.91M. The stock is valued at a price-to-earnings (P/E) ratio of -3.33, price-to-book of 18.87, price-to-sales of 3.96. Over the past 52 weeks the stock has ranged between $2.20 and $7.95, and currently trades 45.3% below its 52-week high.
On profitability, TLSI generates a return on equity (ROE) of 162.57% — well above the market average, a sign of a high-quality business, return on capital employed of -47.35%, an operating margin of -60.00%, a net profit margin of -60.85%.